Everolimus
Проводит Новартис Фарма АГ
Страница компанииLong-term Follow-up Study to Monitor the Growth and Development of Pediatric Patients Previously Treated With Everolimus in Study CRAD001M2301 (EXIST-LT)
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT02338609/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза IV — препарат уже зарегистрирован. Собирают дополнительные сведения о пользе и безопасности при обычном применении.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 0 мес. — 17 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 15 чел. во всех странах исследования.
- Плановая дата окончания (12.2023) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 3 · невключение: 3
Критерии включения
- Pediatric female patients who were on study treatment in study \[CRAD001M2301\] within the past 6 months and have not reached Tanner Stage V or age 16 at the time of completion of \[CRAD001M2301\] or
- Pediatric male patients who were on study treatment in study \[CRAD001M2301\] within the past 6 months and have not reached Tanner Stage V or age 17 at the time of completion of \[CRAD001M2301\]
- Written informed consent according to local guidelines
Критерии невключения
- Pediatric female patients who were on study treatment in CRAD001M2301 and have not reached Tanner Stage V but are within 3 month of turning age 16 or
- Pediatric male patients who were on study treatment in CRAD001M2301 and have not reached Tanner Stage V but are within 3 months of turning age 17
- Any patient who was pregnant prior to start of CRAD001M2305
Источник: ClinicalTrials.gov, NCT02338609 · запись обновлена в реестре 9 августа 2024.
Дизайн и результаты
Что измеряют — первичные конечные точки (6), вторичных — 14
- Number of Participants Who Achieved Tanner Stage V at or Before Age 16 (Females) or 17 (Males) — Annually, up to 14 years from the first visit in parent study CRAD001M2301 (including up to 9 years of follow-up in study CRAD001M2305)
- Number of Participants With Notably Low and Notably High Height and Body Mass Index (BMI) Standard Deviation Score (SDS) — Baseline, annually up to Year 10 of treatment since the start of everolimus in parent study CRAD001M2301 (including a median of 5 years of exposure to everolimus in study CRAD001M2305)
- Endocrine Laboratory Values LH and FSH in Male Participants — Annually, starting at 10-year age until 16-year age (in both studies CRAD001M2301 and CRAD001M2305)
- Endocrine Laboratory Values LH and FSH in Female Participants — Annually, starting at 10-year age until 16-year age (in both studies CRAD001M2301 and CRAD001M2305)
- Endocrine Laboratory Values of Testosterone in Male Participants — Annually, starting at 10-year age until 16-year age (in both studies CRAD001M2301 and CRAD001M2305)
- Endocrine Laboratory Values of Estrogen in Female Participants — Annually, starting at 10-year age until 16-year age (in both studies CRAD001M2301 and CRAD001M2305)
Цель исследования
The primary objective of CRAD001M2305 was to report the long-term effects of everolimus treatment on height, weight and sexual development (using Tanner Stages) in children and adolescents with Tuberous Sclerosis Complex (TSC)-associated with Subependymal Giant Cell Astrocytoma (SEGA). The study monitored the growth and development of pediatric patients with TSC-associated SEGA, previously enrolled in CRAD001M2301 (NCT00789828) until they reach Tanner Stage V, or until age 16 for females or 17 for males whichever occurred first.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT02338609 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.